Case report: Ulcerative colitis-related spondyloarthritis treated with golimumab until 27 weeks of gestation.

Although tumor necrosis factor inhibitors are recommended for preventing flare-ups in pregnant women with ulcerative colitis (UC), studies on golimumab use during pregnancy are scant. Herein, we present a 39-year-old woman with UC and spondyloarthritis. The patient preferred treatment with a long dosing interval that minimally affects the working life of the patient.